Lisa Kerr

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Itamar Raz, Peter W.F. Wilson, Krzysztof Strojek et al. · Diabetes Care · 2009 · 353 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy

John Wyatt, Jaime L. Frías, H. Eugene Hoyme et al. · Diabetic Medicine · 2005 · 104 citations · Full text

Medicine, Maternal Health, Obstetrics +12

A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction

Sarah E. Siegelaar, Lisa Kerr, Scott J. Jacober et al. · Diabetes Care · 2011 · 88 citations · Full text

Medicine, Cardiology, Endocrinology +17

Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

Itamar Raz, Antonio Ceriello, Peter W.F. Wilson et al. · Diabetes Care · 2011 · 78 citations · Full text

Medicine, Cardiology, Geriatric Medicine +17